Assessing Long Term Benefit of Eptinezumab for Chronic Migraine

Amaal Starling, MD, FAHS, FAAN, the associate professor of neurology at Mayo Clinic College of Medicine, discussed findings from a post-hoc analysis of the phase 3 PREVAIL study presented at AHS 2024 assessing eptinezumab in patients with chronic migraine.
Read more: www.neurologyl...
View more AHS content: www.neurologyl...

[@mballer]

On this video, was this trialed against increasing DHA/EPA omega 3 intake?
Is this health or business?

[@mballer]

Why are you putting your latest video under children?
What is that saying about who it was directed towards?
Another drug that sounds like it needs a sales pitch for the patient to use it.
People should be clamoring for it if it had great benefit.
Put it up against a diet and lifestyle change.